<p>Small open-label study of ATR-258 saw fat loss, lean mass gains and better leg power, but no placebo group and just eight weeks long. Losing weight on the new wave of obesity drugs often comes with a side order of lost muscle. Studies suggest that 25–45% of the weight lost on incretin-based medicine</p>